Vascular endothelial growth factor 2

Abstract

Disclosed are human VEGF-2 polypeptides, biologically active, diagnostically or therapeutically useful fragments, analogs, or derivatives thereof, and DNA(RNA) encoding such VEGF-2 polypeptides. Also provided are procedures for producing such polypeptides by recombinant techniques and antibodies and antagonists against such polypeptides. Such polypeptides and polynucleotides may be used therapeutically for stimulating wound healing and for vascular tissue repair. Also provided are methods of using the antibodies and antagonists to inhibit tumor angiogenesis and thus tumor growth, inflammation, diabetic retinopathy, rheumatoid arthritis, and psoriasis.

1 . A method of stimulating angiogenesis in a mammal, comprising: 
 i. introducing a first replication-deficient adenovirus vector comprising a polynucleotide sequence encoding VEGF-B 167  or a fragment or conservative substitution thereof to said mammal; and    ii. introducing a second replication-deficient adenovirus vector comprising a polynucleotide sequence encoding VEGF-A or a fragment or conservative substitution thereof to said mammal,    wherein said first replication-deficient adenovirus vector and said second replication-deficient adenovirus vector are directly delivered to a site in said mammal where there is at least one living cell selected from the group consisting of endothelial cells and cells proximate to endothelial cells of said mammal, and    wherein density of PECAM-1 positive vessels is increased in said site when compared to a site untreated or treated with VEGF-B 167  alone or VEGF-A alone.    
   
   
       2 . The method according to  claim 1 , wherein said at least one living cell is a vascular cell.  
   
   
       3 . The method according to  claim 1 , wherein said endothelial cells are microvascular endothelial cells.  
   
   
       4 . The method according to  claim 1 , wherein said endothelial cells are aortic endothelial cells.  
   
   
       5 . The method according to  claim 1 , wherein said mammal is murine.  
   
   
       6 . The method according to  claim 1 , wherein said mammal is human.  
   
   
       7 . The method according to  claim 1 , wherein 10 7  to 10 13  of vector particles of each adenovirus vector are introduced.  
   
   
       8 . The method according to  claim 1 , wherein expression of the polynucleotide sequence in the first or second vector is driven by a CMV promoter.  
   
   
       9 . A method of stimulating angiogenesis in a mammal, comprising: 
 i. introducing a first replication-deficient adenovirus vector comprising a polynucleotide sequence encoding VEGF-B 167  or a fragment or conservative substitution thereof to said mammal; and    ii. introducing a second replication-deficient adenovirus vector comprising a polynucleotide sequence encoding VEGF-C or a fragment or conservative substitution thereof to said mammal,    wherein said first replication-deficient adenovirus vector and said second replication-deficient adenovirus vector are directly delivered to a site in said mammal where there is at least one living cell selected from the group consisting of endothelial cells and cells proximate to endothelial cells of said mammal, and    wherein density of PECAM-1 positive vessels is increased in said site when compared to a site untreated or treated with VEGF-B 167  alone or VEGF-C alone.    
   
   
       10 . The method according to  claim 9 , wherein said at least one living cell is a vascular cell.  
   
   
       11 . The method according to  claim 9 , wherein said endothelial cells are microvascular endothelial cells.  
   
   
       12 . The method according to  claim 9 , wherein said endothelial cells are aortic endothelial cells.  
   
   
       13 . The method according to  claim 9 , wherein said mammal is murine.  
   
   
       14 . The method according to  claim 9 , wherein said mammal is human.  
   
   
       15 . The method according to  claim 9 , wherein 10 7  to 10 13  of vector particles of each adenovirus vector are introduced.  
   
   
       16 . The method according to  claim 9 , wherein expression of the polynucleotide sequence in the first or second vector is driven by a CMV promoter.  
   
   
       17 . A method of stimulating angiogenesis in a mammal, comprising: 
 i. introducing a first replication-deficient adenovirus vector comprising a polynucleotide sequence encoding VEGF-B 167  or a fragment or conservative substitution thereof to said mammal; and    ii. introducing a second replication-deficient adenovirus vector comprising a polynucleotide sequence encoding VEGF-D or a fragment or conservative substitution thereof to said mammal,    wherein said first replication-deficient adenovirus vector and said second replication-deficient adenovirus vector are directly delivered to a site in said mammal where there is at least one living cell selected from the group consisting of endothelial cells and cells proximate to endothelial cells of said mammal, and    wherein density of PECAM-1 positive vessels is increased in said site when compared to a site untreated or treated with VEGF-B 167  alone or VEGF-D alone.    
   
   
       18 . The method according to  claim 17 , wherein said at least one living cell is a vascular cell.  
   
   
       19 . The method according to  claim 17 , wherein said endothelial cells are microvascular endothelial cells.  
   
   
       20 . The method according to  claim 17 , wherein said endothelial cells are aortic endothelial cells.  
   
   
       21 . The method according to  claim 17 , wherein said mammal is murine.  
   
   
       22 . The method according to  claim 17 , wherein said mammal is human.  
   
   
       23 . The method according to  claim 1 , wherein 10 7  to 10 13  of vector particles of each adenovirus vector are introduced.  
   
   
       24 . The method according to  claim 1 , wherein expression of the polynucleotide sequence in the first or second vector is driven by a CMV promoter.